Adjuvant trastuzumab for breast cancer: assessing HER2/neu status incurs more costs for treatment
- PMID: 16293849
- PMCID: PMC1285108
- DOI: 10.1136/bmj.331.7526.1202
Adjuvant trastuzumab for breast cancer: assessing HER2/neu status incurs more costs for treatment
Comment on
-
Adjuvant trastuzumab for breast cancer.BMJ. 2005 Nov 5;331(7524):1035-6. doi: 10.1136/bmj.331.7524.1035. BMJ. 2005. PMID: 16269471 Free PMC article. No abstract available.
References
-
- Ross JS, Fletcher JA, Linette GP, et al. The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 2003;8: 307-25. - PubMed
-
- Press MF, Sauter G, Bernstein L, et al. Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res 2005;11: 6598-607. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous